Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

4.70p
   
  • Change Today:
    -0.43p
  • 52 Week High: 16.50
  • 52 Week Low: 4.68
  • Currency: UK Pounds
  • Shares Issued: 201.37m
  • Volume: 161,916
  • Market Cap: £9.46m
  • RiskGrade: 510

Synairgen to collaborate with University of Southampton on observational study

By Iain Gilbert

Date: Monday 05 Sep 2022

LONDON (ShareCast) - (Sharecast News) - Drug discovery outfit Synairgen will collaborate with the University of Southampton on an observational study aimed at exploring and better understanding acute respiratory viral infections and recovery.
Synairgen said the UNIVERSAL trial, being led by the university's clinical trials unit, will look to develop a prospective longitudinal clinical database of respiratory viral infections in hospitalised patients to inform the development of potential antivirals to treat severe viral lung infections caused by seasonal viruses and emerging viral threats.

The AIM-listed group said the trial, which aims to recruit 1,000 patients, will be initiated at ten sites across the UK. Synairgen will provide viral testing equipment and nursing staff at its Southampton clinical trial site, while funding for the trial will be provided by Janssen.

Chief executive Richard Marsden said: "The Covid-19 pandemic highlighted the important link between research and clinical care and its impact on the timely development of much-needed antivirals for severe lung viral infections caused by seasonal viruses and emerging respiratory viral threats.

"Our collaboration on the UNIVERSAL trial will help provide a better understanding of what could predict clinical outcomes in patients hospitalised with respiratory symptoms due to infection with a range of respiratory viruses. The UNIVERSAL trial will help to further inform the development programme of SNG001, our investigational broad-spectrum antiviral."

As of 1140 BST, Synairgen shares were up 3.55% at 23.20p.





Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Synairgen Market Data

Currency UK Pounds
Share Price 4.70p
Change Today -0.43p
% Change -8.38 %
52 Week High 16.50
52 Week Low 4.68
Volume 161,916
Shares Issued 201.37m
Market Cap £9.46m
RiskGrade 510

Synairgen Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
66.84% above the market average66.84% above the market average66.84% above the market average66.84% above the market average66.84% above the market average
74.07% above the sector average74.07% above the sector average74.07% above the sector average74.07% above the sector average74.07% above the sector average
Price Trend
76.34% below the market average76.34% below the market average76.34% below the market average76.34% below the market average76.34% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Synairgen Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
14:47 54 @ 5.49p
14:34 8,846 @ 4.70p
14:20 62,500 @ 4.80p
13:39 1,295 @ 4.75p
13:36 40,002 @ 4.70p

Synairgen Key Personnel

CEO Richard J Marsden

Top of Page